Follicular Lymphoma · line 1 · Bendamustine + Rituximab (BR), 6 cycles

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	1
Track	standard
Linked regimen	`REG-BR-STANDARD`

ID	`IND-FL-1L-BR`
Type	Indication
Status	reviewed 2026-04-27 \| pending_clinical_signoff
Diseases	`DIS-FL`
Sources	`SRC-ESMO-LYMPHOMA-2025` `SRC-NCCN-BCELL-2025`

Notes

STUB — pending Clinical Co-Lead sign-off. Reuses REG-BR-STANDARD (same drugs as HCV-MZL track).

Used By

Algorithms

ALGO-FL-1L - ALGO-FL-1L